收藏切换
Clinical efficacy and safety of apatinib in advanced gastric cancer with different blood supply
收藏切换
PDF
Qi CHEN1, 2, Chang-lu HU1, Xin WEI2, Dan WANG2, Jia-jia LIU2, Qi-zhi ZHU2, Wei-ping XU2, 3
Chinese Journal of New Drugs | 2023, 32(15) : 1546 - 1551
Less
收藏切换
Chinese Journal of New Drugs | 2023, 32(15): 1546-1551
Clinical efficacy and safety of apatinib in advanced gastric cancer with different blood supply
Full
Qi CHEN1, 2, Chang-lu HU1, Xin WEI2, Dan WANG2, Jia-jia LIU2, Qi-zhi ZHU2, Wei-ping XU2, 3
Affiliations
  • 1Department of Medical Oncology, The First Affiliated Hospital of USTC/Anhui Provincial Hospital, Hefei 230031, China
  • 2University of Science and Technology of China, Hefei 230026, China
  • 3Department of Geriatrics, The First Affiliated Hospital of USTC/Anhui Provincial Hospital/Gerontology Institute of Anhui Province, Hefei 230001, China
Published: 2023-08-15
Outline
收藏切换
Objective:

To investigate the clinical efficacy and safety of apatinib in advanced gastric cancer with different blood supply.

Methods:

The clinical data of 45 patients with advanced gastric cancer with different blood supply treated with apatinib were analyzed retrospectively. The patients with the difference of CT values between arterial phase and plain scan at the same level ≥40 HU were included in group A, ≥20 HU and <40 HU in group B, and <20 HU in group C. The therapeutic effects, serum carcinoembryonic antigen (CEA), carbohydrate antigen199 (CA199), survival and safety of the three groups were compared.

Results:

The objective remission rate and disease control rate of group A were significantly higher than those of group B and group C (P<0.05). After treatment, the CEA and CA199 of the three groups decreased significantly, and through pairwise comparison, the CEA and CA199 of the three groups ranked C, B and A from high to low. There was significant difference in PFS among the three groups (P<0.05). After pairwise comparison, the PFS of the three groups ranked A, B and C from high to low. The difference of adverse events among the three groups was not statistically significant (P>0.05).

Conclusion:

The clinical efficacy of apatinib in rich blood supply advanced gastric cancer is better than that in lack of blood supply advanced gastric cancer. It has the same safety in rich blood supply advanced gastric cancer and lack of blood supply advanced gastric cancer.

apatinib  /  different blood supply  /  advanced gastric cancer  /  clinical efficacy  /  safety
Qi CHEN, Chang-lu HU, Xin WEI, Dan WANG, Jia-jia LIU, Qi-zhi ZHU, Wei-ping XU. Clinical efficacy and safety of apatinib in advanced gastric cancer with different blood supply[J]. Chinese Journal of New Drugs, 2023 , 32 (15) : 1546 -1551 .
Year 2023 volume 32 Issue 15
PDF
29
6
Cite this Article
BibTeX
Article Info
  • Online Date:2026-03-05
  • Published:2023-08-15
Article Data
Affiliations
History
  • Accepted:2023-05-10
Affiliations
    1Department of Medical Oncology, The First Affiliated Hospital of USTC/Anhui Provincial Hospital, Hefei 230031, China
    2University of Science and Technology of China, Hefei 230026, China
    3Department of Geriatrics, The First Affiliated Hospital of USTC/Anhui Provincial Hospital/Gerontology Institute of Anhui Province, Hefei 230001, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT